Trial Profile
A double-blind dose-escalating study of LT-3001 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2019
Price :
$35
*
At a glance
- Drugs LT 3001 (Primary)
- Indications Stroke
- Focus Adverse reactions; First in man
- 13 Jun 2019 Status changed from recruiting to completed, according to a Lumosa Therapeutics media release.
- 13 Jun 2019 Results presented in a Lumosa Therapeutics Media Release.
- 03 Aug 2017 Planned number of patients changed to 80.